AI assistant
Sending…
Gain Therapeutics, Inc. — Director's Dealing 2021
Mar 30, 2021
34440_dirs_2021-03-29_c2f139af-4455-4cb9-b479-2e30bc212268.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Gain Therapeutics, Inc. (GANX)
CIK: 0001819411
Period of Report: 2021-03-17
Reporting Person: Bellotto Manolo (N/A)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option | $3.37 | 2030-09-24 | Common Stock (123309) | Direct |
Footnotes
F1: 41,109 of the options will be fully vested and exercisable on September 25, 2021, and the remaining options will vest in monthly installments of 3,425 until September 25, 2023.
More from Gain Therapeutics, Inc.
Regulatory Filings
2026
May 26
Proxy Solicitation & Information Statement
2026
Apr 28
Director's Dealing
2026
Mar 27
Director's Dealing
2026
Mar 27
Regulatory Filings
2026
Mar 18
Investor Presentation
2026
Feb 3
Regulatory Filings
2025
Dec 18
Regulatory Filings
2025
Dec 3
Capital/Financing Update
2025
Nov 28
Capital/Financing Update
2025
Nov 28